142,904 Shares in Ralliant Corporation $RAL Purchased by Walleye Capital LLC

Walleye Capital LLC bought a new position in shares of Ralliant Corporation (NYSE:RAL) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 142,904 shares of the company’s stock, valued at approximately $10,522,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RAL. Viking Global Investors LP bought a new stake in shares of Ralliant in the second quarter valued at approximately $257,200,000. State Street Corp bought a new position in Ralliant during the 2nd quarter worth $213,096,000. Millennium Management LLC raised its holdings in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares in the last quarter. Norges Bank acquired a new position in Ralliant in the 4th quarter valued at $124,687,000. Finally, Invesco Ltd. lifted its position in shares of Ralliant by 90.1% during the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock valued at $169,309,000 after acquiring an additional 1,835,128 shares during the period.

Ralliant Trading Up 1.3%

Shares of RAL stock opened at $72.34 on Friday. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The stock’s fifty day moving average price is $68.60 and its two-hundred day moving average price is $55.44. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. The company has a market cap of $8.00 billion, a PE ratio of -6.67, a P/E/G ratio of 2.65 and a beta of 1.60.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts predict that Ralliant Corporation will post 2.87 EPS for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is presently -1.84%.

Wall Street Analyst Weigh In

RAL has been the topic of a number of recent analyst reports. Morgan Stanley raised their price target on Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. Evercore started coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Friday, July 31st. BMO Capital Markets assumed coverage on shares of Ralliant in a report on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price on the stock. Finally, Oppenheimer boosted their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ralliant currently has an average rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.